FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials
$1699
Premier pro price: $1614 (save 5%)
Because a phase 1 clinical trial initially introduces an investigational new drug into human subjects, appropriate CGMP help ensure subject safety. It is important to implement quality control (QC) principles to the manufacture of phase 1 investigational drugs (i.e., interpreting and implementing CGMP consistent with good scientific methodology), which foster CGMP activities that are more appropriate for phase 1 clinical trials, improve the quality of phase 1 investigational drugs, and facilitate the initiation of investigational clinical trials in humans while continuing to protect trial subjects.
The following steps to establish the appropriate manufacturing environment for phase 1 investigational drugs should be taken:
- A comprehensive and systematic evaluation of the manufacturing setting (i.e., product environment, equipment, process, personnel, materials) to identify potential hazards
- Appropriate actions prior to and during manufacturing to eliminate or mitigate potential hazards to safeguard the quality of the phase 1 investigational drug
Review the FDA recommendations and requirements for implementing a compliant program for the phase 1 clinical program.
The following topics will be discussed to provide the foundation and basis for advancing drugs into clinical development from research and providing required information to the FDA regarding these products.
- Overview of Good Manufacturing Practices
- GMP Requirements for a Phase 1 Study
- Personnel
- QC Function
- Facility and Equipment
- Control of components, containers and closures
- Manufacturing & Records
- Laboratory Controls
- Vendor selection & management
- Process Validation
- Special Considerations
- Multi-product facilities
- Biologics
- Sterile products
- Combination products
- Providing relevant information in the IND application
Course benefit:
This workshop will review the current regulations, guidance documents for early stage manufacturing and GMPs in detail. Regulatory strategies and logistical considerations for early development stage product, including vendor selection and management, stability, labeling, and documentation requirements will also be reviewed and explored.
Learning Objectives:
To gain an understanding of the requirements for drugs entering into phase 1 clinical development and the minimum FDA requirements for phase I GMPs. To learn practical applications for implementing manufacturing and quality strategies to meet FDA requirements.
Areas Covered:
Day 1 Topics
- Overview of GMP requirements
- GMP Requirements for a Phase 1 Study
- Personnel documentation and requirements
- QC Function procedures and requirements
- Facility and Equipment requirements
- Control of components, containers and closures – methods and specs
- Manufacturing & Records during phase 1 studies with an eye toward later development
Day 2 Topics
- Vendor selection & management
- Process Validation to conduct for phase 1 clinical supply process
- Specific requirements for various types of products: biologics, combinations, sterile products
- Multi-product facilities considerations
- Preparing relevant SOPs for early stage development
- Providing relevant information in the IND application
Who will Benefit:
- Directors
- Manager
- Supervisors
- Lead workers in Regulatory Affairs Quality Assurance and Quality Control
- Workers who will prepare GMP documents for early phase products
- Workers who will review GMP documents for early phase products
|
Day 01(8:30 AM - 4:00 PM)
|
Day 02(8:30 AM - 4:00 PM)
|
Seminar (Price/Register)
Seminar Fee Includes:
Other Registration Option
- Download the Order Form
- Fill this form with attendee details & payment details
- Fax your PO to 1-888-883-7697 or,
- Email it to cs@compliance.world
Payment Mode
By Check -
Pay your check issued from the payee to "Redstone Learning Inc." (Our Parent Company) and mail the check to –Compliance.world (Redstone Learning Inc.)
1180
Avenue of the Americas,
8th Floor, New York,
NY 10036
Media Partners
If you wish to partner with us for this event
please contact us: partner
or
call us: 1-866-978-0800
Media Partner Benefits
- Logo and company data on the event website.
- Logo on the conference material distributed during the conference.
- Media Partner’s brochure distributed along with conference material.
- Logo on all the mailings before and after the event.
- 10% discount to media partner's subscribers.
Media Partner to do
- Banner (min 728x90 or 468x60) on the Media Partner website.
- Insertion of the event in the event calendar, both printed and/or online.
- Announcement article of the conference on the Magazine and/or Website.
- Dedicated email blast to all subscribers of Media Partner.
- Article on the Magazine and/or Website after the conference.
Sponsors
If you wish to partner with us for this event
please contact us: sponsor@compliance.world or
call us: 1-866-978-0800
Speaker: Peggy J Berry,
Peggy J. Berry, MBA, RAC, is the President & CEO at Synergy Consulting where she provides consulting services to companies in all aspects of drug development. She also provides group and one-on-one training in drug development, regulatory affairs and project management topics. Prior to founding Synergy Consulting in 2015, she was Vice President of Regulatory Affairs at Insmed (2/2015-5/2015) where she was responsible for the development and implementation of global regulatory strategies and the management and oversight of the regulatory affairs department. Prior to Insmed, she was Vice President of Regulatory Affairs and Quality at Amarin (3/2009-2/2014). She has also held a variety of senior level positions at Dyax (5/2006-3/2009), MGI Pharma (now Eisai; 7/2005-5/2006), AstraZeneca (10/2001-7/2005), and Dey Pharma (now Mylan; 12/1997-10/2001). She has also held Regulatory Affairs roles within two clinical contract research organizations (ILEX Oncology and Cato Research Ltd; 1992-1997) and has worked in review divisions at the FDA (1985-1992). In addition, Ms. Berry consults for a number of companies in the regulatory and quality area, conducts a number of training courses, and is active in the Regulatory Affairs Professionals Society. She is the editor of the 2010 book “Choosing the Right Regulatory Career” (RAPS, MD) and author of the 2011 book “Communication & Negotiation” (RAPS, MD).
